New drug HCB101 enters human trials for tough cancers

NCT ID NCT05892718

Recruiting now Disease control Sponsor: FBD Biologics Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether the experimental drug HCB101 is safe and can shrink tumors in people with advanced solid tumors or non-Hodgkin lymphoma that has come back or not responded to other treatments. About 80 adults aged 18 and older will receive the drug by IV. The main goals are to check for side effects and find the best dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma neoplasm non-Hodgkin lymphoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR REFRACTORY NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Carolina BioOncology
RECRUITING

Huntersville, North Carolina, 28078, United States
Greenville Hospital System University Medical Center (ITOR)
RECRUITING

Greenville, South Carolina, 29605, United States
Hangzhou First People's Hospital
RECRUITING

Hangzhou, Zhejiang, 310000, China
Hematology-Oncology Associates of the Treasure Coast
RECRUITING

Port Saint Lucie, Florida, 34952, United States
National Taiwan University Hospital
RECRUITING

Taipei, 10002, Taiwan
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare
RECRUITING

New Taipei City, 23561, Taiwan
Taipei Veterans General Hospital
RECRUITING

Taipei, 11217, Taiwan
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.